Xilio Therapeutics, Inc.

NasdaqGS XLO

Xilio Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.79

Xilio Therapeutics, Inc. Price to Earnings Ratio (P/E) is -0.79 on January 14, 2025, a -365.65% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Xilio Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.14 on February 22, 2024, which is 81.97% above the current Price to Earnings Ratio (P/E).
  • Xilio Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.01 on November 04, 2024, which is -28.20% below the current Price to Earnings Ratio (P/E).
  • Xilio Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.55.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NasdaqGS: XLO

Xilio Therapeutics, Inc.

CEO Dr. Rene Russo BCPS, Pharm.D.
IPO Date Oct. 22, 2021
Location United States
Headquarters 828 Winter Street
Employees 73
Sector Health Care
Industries
Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Similar companies

MNOV

MediciNova, Inc.

USD 1.91

-4.02%

RAPT

RAPT Therapeutics, Inc.

USD 1.10

-9.09%

ADAG

Adagene Inc.

USD 1.80

1.12%

CNTB

Connect Biopharma Holdings Limited

USD 1.06

-2.75%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

AVTE

Aerovate Therapeutics, Inc.

USD 2.47

-1.20%

DSGN

Design Therapeutics, Inc.

USD 4.02

-2.19%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

CSBR

Champions Oncology, Inc.

USD 9.67

5.45%

TYRA

Tyra Biosciences, Inc.

USD 15.94

5.56%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email